CD8A and cancer: This second system consists of slower growing M257-A2 melanoma cells engineered to express the cancer-testis antigen NY-ESO-1, and CD8+ T cells transduced with a cognate TCR that recognizes the NY-ESO-1 target tumor cell antigen.